E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 11/22/2013 in the Prospect News Convertibles Daily.

Midday Commentary: American Residential adds on debut; new Forestar, GAIN Capital quiet

By Rebecca Melvin

New York, Nov. 22 -American Residential Properties Inc.'s newly priced 3.25% exchangeable senior notes traded better at 101.5 bid, 102.5 offered early Friday after the Memphis, Tenn.-based heating, air conditioning, ventilation and plumbing services provider priced $100 million of the five-year notes at the cheap end of talk, according to a market source.

American Residential shares were up about a nickel, or 0.3%, to $17.39.

Also new to the convertibles market on Friday were Forestar Group Inc.'s $135 million of 6% tangible equity units, which priced at the midpoint of talked terms, and GAIN Capital Holdings Inc.'s upsized $70 million of 4.125% convertible senior notes, which priced at terms that were mixed compared to talk.

Those new convertibles were quiet in secondary market action. But shares of Forestar, an Austin, Texas-based real estate, mineral and fiber resources company, were up 65 cents, or 3.4% at $19.74 at late morning; and shares of GAIN Capital, a Bedminster, N.J.-based trading services provider, were unchanged at $8.88.

Back in established issues, trading activity in the convertibles market was described as "dead" by several market players. Forestar Group's existing 3.75% convertibles due 2032 showed up on the Trace tape, changing hands at 108.875. A previous level for that convertible wasn't known.

Also BioMarin Pharmaceutical Inc.'s dual tranches, including a 0.75% convertible due 2018 and a 1.5% convertible due 2020, which priced in early October, were seen in trade at 107.9 and 109, respectively, according to Trace data.

On Nov. 19, a panel of the Food and Drug Administration recommended that BioMarin's Vismizim for patients with a rare genetic disorder that causes skeletal malformation be approved for sale in the United States. That drug is up for a ruling by the FDA at the end of February. Getting one step closer to regulatory approval makes BioMarin more attractive to potential acquirers.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.